510(k) device
Esensor Cystic Fibrosis Carrier Detection System, Model Esensor 4800
Clinical Micro Sensors, Inc. · System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection (NUA, Class II) · First FDA decision Jan 19, 2006, newest Mar 28, 2006Genetic and newborn screening
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
0
Naming "Esensor"
MAUDE reports
0
Brand "Esensor", since 2015
PubMed studies
32
Mentioning "Esensor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Esensor Cystic Fibrosis Carrier Detection System, Model Esensor 4800
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K060543 · Decided Mar 28, 2006 · 27 days after receipt
Device type: System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection (NUA) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Esensor", any status and sponsor, newest update first.
No registered device study names "Esensor".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Esensor", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NUA
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Esensor"[tiab]. The summary above synthesizes these.
- Evaluation of Performance Characteristics of Panther Fusion Assays for Detection of Respiratory Viruses from Nasopharyngeal and Lower Respiratory Tract Specimens.
Sam SS, Caliendo AM, Ingersoll J, et al. · J Clin Microbiol · 2018Comparative Study, Evaluation Study
- Comparison of performance of three commercial platforms for warfarin sensitivity genotyping.
Babic N, Haverfield EV, Burrus JA, et al. · Clin Chim Acta · 2009Comparative Study
- Analytical Sensitivity Comparison between Singleplex Real-Time PCR and a Multiplex PCR Platform for Detecting Respiratory Viruses.
Parker J, Fowler N, Walmsley ML, et al. · PLoS One · 2015Comparative Study, Research Support, Non-U.S. Gov't
- Clinical Performance of the Novel GenMark Dx ePlex Blood Culture ID Gram-Positive Panel.
Carroll KC, Reid JL, Thornberg A, et al. · J Clin Microbiol · 2020Multicenter Study, Research Support, Non-U.S. Gov't
- Validation of a solid-phase electrochemical array for genotyping hepatitis C virus.
Sam SS, Steinmetz HB, Tsongalis GJ, et al. · Exp Mol Pathol · 2013Research Support, Non-U.S. Gov't, Validation Study
- Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infinitiࡊ and Luminex CYP2C19 panels.
Lee CC, McMillin GA, Babic N, et al. · Clin Chim Acta · 2011Comparative Study
- Flow cytometric assay for genotyping cytochrome p450 2C9 and 2C19: comparison with a microelectronic DNA array.
Pickering JW, McMillin GA, Gedge F, et al. · Am J Pharmacogenomics · 2004Comparative Study
- Epidemic 2014 enterovirus D68 cross-reacts with human rhinovirus on a respiratory molecular diagnostic platform.
McAllister SC, Schleiss MR, Arbefeville S, et al. · PLoS One · 2015Research Support, N.I.H., Extramural
- Bioelectronic sensor technology for detection of cystic fibrosis and hereditary hemochromatosis mutations.
Bernacki SH, Farkas DH, Shi W, et al. · Arch Pathol Lab Med · 2003Evaluation Study, Research Support, U.S. Gov't, P.H.S.
- Comparison of the GenMark Diagnostics eSensor respiratory viral panel to real-time PCR for detection of respiratory viruses in children.
Pierce VM, Hodinka RL · J Clin Microbiol · 2012Evaluation Study
- Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping.
Maurice CB, Barua PK, Simses D, et al. · Clin Chim Acta · 2010Comparative Study, Research Support, Non-U.S. Gov't
- Comparative Performance of the Luminex NxTAG Respiratory Pathogen Panel, GenMark eSensor Respiratory Viral Panel, and BioFire FilmArray Respiratory Panel.
Popowitch EB, Kaplan S, Wu Z, et al. · Microbiol Spectr · 2022
Other devices of this type
Also filed under product code NUA.
- xTAG Cystic Fibrosis 39 Kit v2Luminex Molecular Diagnostics, Inc. · 510(k) 2016
- Tag-It Cystic Fibrosis KitTm Bioscience Corporation · De Novo 2006
- Xtag CF60 Kit V2Luminex Molecular Diagnostics, Inc. · 510(k) 2009
- Verigene Cftr Nucleic Acid Test and Verigene Cftr Polyt Nucleic Acid TestNanosphere, Inc. · 510(k) 2009
- Esensor Cf Genotyping Testm Esensor SystemOsmetech Molecular Diagnostics · 510(k) 2009
- Inplex Cf Molecular TestThird Wave Technologies, Inc. · 510(k) 2008
- Cystic Fibrosis Genotyping Assay, Model 6L20-01Celera Diagnostics · 510(k) 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.